[CYTK] Cytokinetics, Incorporated

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 384.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 12.4 Change: 0.6 (5.08%)
Ext. hours: Change: 0 (0%)

chart CYTK

Refresh chart

Strongest Trends Summary For CYTK

CYTK is in the medium-term up 29% above S&P in 1 month and up 76% in 6 months. In the long-term down -30% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a st

Fundamental Ratios
Shares Outstanding39.62 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -43.32% Sales Growth - Q/Q-79.71% P/E
P/E To EPS Growth P/S8.86 P/BV4.57 Price/Cash Per Share3.56
Price/Free Cash Flow-8.36 ROA-12.09% ROE-17.56% ROI
Current Ratio4.37 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin-34.34% Net Profit Margin-34.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-32.09 M Cash From Operating Activities34.36 M Gross Profit
Net Profit-8.87 M Operating Profit-8.91 M Total Assets122.21 M Total Current Assets110.81 M
Total Current Liabilities25.39 M Total Debt Total Liabilities38.06 M Total Revenue4.41 M
Technical Data
High 52 week10.73 Low 52 week5.91 Last close10.41 Last change-2.98%
RSI60.33 Average true range0.75 Beta1.31 Volume193.45 K
Simple moving average 20 days10.67% Simple moving average 50 days19.88% Simple moving average 200 days29.91%
Performance Data
Performance Week3.38% Performance Month30.94% Performance Quart31.77% Performance Half62.66%
Performance Year20.35% Performance Year-to-date64.72% Volatility daily4.11% Volatility weekly9.19%
Volatility monthly18.84% Volatility yearly65.27% Relative Volume217.31% Average Volume661.5 K
New High New Low

News

2019-06-24 16:00:00 | Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference

2019-06-13 14:40:35 | Could The Cytokinetics, Incorporated NASDAQ:CYTK Ownership Structure Tell Us Something Useful?

2019-06-12 16:00:00 | Cytokinetics to Present at the JMP Securities Life Sciences Conference

2019-05-30 07:30:00 | Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

2019-05-09 23:36:33 | Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 20:24:25 | Cytokinetics Inc CYTK Q1 2019 Earnings Call Transcript

2019-05-09 18:05:10 | Cytokinetics CYTK Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 16:54:27 | Cytokinetics: 1Q Earnings Snapshot

2019-05-09 16:00:00 | Cytokinetics Reports First Quarter 2019 Financial Results

2019-05-08 16:00:00 | Cytokinetics to Hold Annual Meeting of Stockholders

2019-05-06 10:29:15 | Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters

2019-05-06 09:18:00 | Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints

2019-05-05 13:11:00 | Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting

2019-05-02 10:32:02 | Will Cytokinetics CYTK Report Negative Earnings Next Week? What You Should Know

2019-04-25 16:00:00 | Cytokinetics to Announce First Quarter Results on May 9, 2019

2019-04-25 13:47:24 | What Are Analysts Expecting From Cytokinetics, Incorporated NASDAQ:CYTK In The Next Couple Of Years?

2019-04-18 10:33:02 | Will Cytokinetics CYTK Report Negative Q1 Earnings? What You Should Know

2019-04-01 16:00:00 | Cytokinetics to Present at April Investor Conferences

2019-04-01 07:00:00 | New Research Coverage Highlights International Paper, Square, Sealed Air, Calix, e.l.f. Beauty, and Cytokinetics — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-03-27 10:55:02 | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

2019-03-21 07:51:16 | The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

2019-03-20 16:51:00 | Here's Why Cytokinetics Stock Jumped Today

2019-03-20 08:30:00 | Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

2019-03-18 16:00:00 | Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

2019-03-11 16:04:38 | Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19

2019-03-07 16:10:27 | Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting

2019-03-07 10:38:02 | Some Cytokinetics Shareholders Are Down 43%

2019-03-07 06:48:03 | Cytokinetics Inc CYTK Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-28 07:30:00 | Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day

2019-02-22 16:53:09 | Amgen Starts Phase III Enrollment for Heart Failure Drug

2019-02-22 01:46:10 | Edited Transcript of CYTK earnings conference call or presentation 21-Feb-19 9:30pm GMT

2019-02-21 22:18:06 | Cytokinetics Inc CYTK Q4 2018 Earnings Conference Call Transcript

2019-02-21 17:15:10 | Cytokinetics CYTK Reports Q4 Loss, Tops Revenue Estimates

2019-02-21 16:11:29 | Cytokinetics: 4Q Earnings Snapshot

2019-02-21 16:00:00 | Cytokinetics Reports Fourth Quarter 2018 Financial Results

2019-02-21 08:30:00 | Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

2019-02-20 09:00:00 | Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

2019-02-14 10:45:03 | The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

2019-02-14 10:31:03 | Will Cytokinetics CYTK Report Negative Earnings Next Week? What You Should Know

2019-02-13 08:36:01 | 5 Tiny Biotech Stocks With Superb Growth Potential

2019-02-07 16:00:00 | Cytokinetics to Announce Fourth Quarter Results on February 21, 2019

2019-01-22 07:30:00 | Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA

2019-01-04 07:24:12 | Could Cytokinetics, Incorporated’s NASDAQ:CYTK Investor Composition Influence The Stock Price?

2018-12-22 02:51:56 | Hedge Funds Are Dumping Cytokinetics, Inc. CYTK

2018-12-10 07:30:00 | Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND

2018-12-05 07:30:00 | Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor

2018-12-03 07:57:40 | Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More

2018-11-27 08:00:00 | Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-27 07:30:00 | Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS

2018-11-26 16:00:00 | Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND